The WMCTG is comprised of over 20 major cancer centers around the world. Their mission is to maintain active clinical trials year round in an effort to constantly improve the understanding and continue to offer patients the most effective treatments for Waldenström's macroglobulinemia. By maintaining an extensive contingent of collaborating centers, they hope to be better able to enroll patients in the trials without delay. Not only does the WMCTG allow more convenient patient access to treatment, but will also facilitate completion of clinicl tials in a more timely manner.
At www.wmctg.org you can find more information about the physicians belonging to the WMCTG, including six European members and see in what WM clinical trials each one of them is involved.
More information on WM and clinical trials is available at the following websites:
NIH Clinical Trials: www.clinicaltrials.gov
EU Clinical Trials Register: www.clinicaltrialsregister.eu
National Cancer Institute: www.cancer.gov